Livestream

Antipsychotic Medications: Past, Present, and Future

|

Pricing

Information

Date & Time

Learning Objectives

Participants will be able to:

  • Explain how antipsychotic medications were discovered by serendipity.

  • Describe the basic pharmacology of antipsychotic medications in general and the rationale for choosing medications in clinical practice.

  • Identify at least two new antipsychotic medications with novel mechanisms of action and their potential to improve adherence due to better side effect profile.

  • Summarize proposed future psychopharmacological interventions for schizophrenia spectrum disorders.

Educational Goal

The educational goal of this presentation is to increase understanding of antipsychotic medications.

Description

This presentation will cover the psychopharmacology of antipsychotic medications. It will include a brief history of antipsychotic medications, the current state of the field, and new and emerging medications with their potential benefits, risks, and impact on the burden of severe mental illness.

Target Audience

  • Counselor
  • Marriage & Family Therapist
  • Psychologist
  • Social Worker
  • Substance Use Disorder Professionals

Presenters

Olaoluwa Okusaga, MD
Olaoluwa (Ola) Okusaga is an Associate Professor of Psychiatry and a Board-Certified Psychiatrist with clinical interest in the psychopharmacological treatment of adult patients with schizophrenia spectrum and other psychotic disorders. He attended Ogun State University Medical School in Shagamu, Nigeria, completed a Master of Science in Public Health Research at the University of Edinburgh, Scotland and undertook psychiatry residency training at Saint Elizabeth Hospital Residency Program, Washington, DC. He is the Clinical Lead for the Bipolar and Schizophrenia Treatment (BeST) clinic and Director of the repetitive transcranial magnetic stimulation (rTMS) clinic at the Michael E. DeBakey VA Medical Center in Houston, Texas. He is involved in medical student, psychiatry resident, psychology intern and physician assistant training at the Michael E. DeBakey VA Medical Center. His primary area of research is metabolic syndrome and its sequelae in people with severe mental illness. His research involves the evaluation of the associations between inflammatory biomarkers, endothelial markers, and lipids metabolic syndrome. His current research focus is the elucidation of the underlying mechanisms of metabolic syndrome-related cognitive impairment during mid to late-life in patients with schizophrenia. He is currently funded by the Veterans Affairs R&D as the PI of a genomic study in schizophrenia and as the Houston Site Investigator of the Million Veteran Program. He has over 40 publications in peer-reviewed journals and four book chapters.

Financially Sponsored By

  • APA Division 18: Psychologists in Public Service